Holen Sie sich die Stockscreener-App
18.68
0.95%
-0.1661
Schlusskurs vom Vortag:
$18.85
Offen:
$18.88
24-Stunden-Volumen:
3.52M
Relative Volume:
0.52
Marktkapitalisierung:
$5.81B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-277.02M
KGV:
-20.03
EPS:
-0.9328
Netto-Cashflow:
$-91.36M
1W Leistung:
+1.91%
1M Leistung:
+55.97%
6M Leistung:
+261.12%
1J Leistung:
+1,215%
1-Tages-Spanne:
$17.91
$19.09
1-Wochen-Bereich:
$17.24
$19.09
52-Wochen-Spanne:
$1.3301
$24.28
Erasca Inc Stock (ERAS) Company Profile
Firmenname
Erasca Inc
Sektor
Branche
Telefon
(858) 465-6511
Adresse
3115 MERRYFIELD ROW, SAN DIEGO
Compare ERAS vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ERAS
Erasca Inc
|
18.68 | 5.74B | 0 | -277.02M | -91.36M | -0.9328 |
VRTX
Vertex Pharmaceuticals Inc
|
524.31 | 134.02B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
672.45 | 68.59B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
921.42 | 58.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
320.25 | 41.76B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
191.81 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
Erasca Inc Stock (ERAS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-27 | Fortgesetzt | Mizuho | Outperform |
| 2026-01-07 | Eingeleitet | Piper Sandler | Overweight |
| 2025-10-16 | Eingeleitet | Stifel | Buy |
| 2025-09-03 | Herabstufung | BofA Securities | Buy → Underperform |
| 2025-08-18 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2025-03-26 | Eingeleitet | Raymond James | Outperform |
| 2024-11-18 | Eingeleitet | Jefferies | Buy |
| 2024-03-11 | Eingeleitet | CapitalOne | Overweight |
| 2024-01-05 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-10-11 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-03-30 | Eingeleitet | Mizuho | Buy |
| 2023-02-24 | Eingeleitet | Goldman | Buy |
| 2023-02-03 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
Alle ansehen
Erasca Inc Aktie (ERAS) Neueste Nachrichten
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A - GlobeNewswire
ERAS DEADLINE ALERT: Erasca, Inc. (ERAS) Investors with - GlobeNewswire
ERAS Investors Have Opportunity to Lead Erasca, Inc. Securities Fraud Lawsuit with the Schall Law Firm - PR Newswire
B of A Securities Downgrades Erasca (ERAS) - MSN
Erasca (ERAS) Faces Securities Class Action After Stock Declines 48% on Drug Safety and IP Concerns-- HBSS - GlobeNewswire
Erasca (ERAS) Faces Securities Class Action After Stock Declines 48% on Drug Safety and IP Concerns-- HBSS - GlobeNewswire Inc.
Erasca, Inc. Notice of August 10, 2026 Application Deadline for Class Action LawsuitContact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline - StreetInsider
Deadline Alert: Erasca, Inc. (ERAS) Shareholders Who Lost - GlobeNewswire
ERAS UPCOMING DEADLINE: Levi & Korsinsky Alerts Erasca, - GlobeNewswire
ERAS CLASS ACTION NOTICE: Faruqi & Faruqi, LLP Reminds - GlobeNewswire
ERAS INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Erasca, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
ERAS INVESTOR REMINDER: Erasca, Inc. Investors Have Until August 10, 2026 to Seek Lead Plaintiff Role - mykxlg.com
ERAS Stockholders Have RightsIf you Lost Money Investing in Erasca, Inc. Contact Robbins LLP for Information About Recovering Your Losses - Morningstar
Is Erasca’s (ERAS) Shift Into Russell Growth Indexes Reframing Its Core Investment Story? - simplywall.st
ERAS INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Erasca, Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
ERAS Investors Have Opportunity to Lead Erasca, Inc. Securities Fraud Lawsuit - Barchart.com
ERAS SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Erasca, Inc. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
ERASErasca Inc Revenue Breakdown - Finviz
ERAS SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Erasca, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Erasca, Inc. Files Form 8-K: Company Information, Stock Details, and SEC Filing Summary for June 26, 2026 - Minichart
ERAS DEADLINE: Levi & Korsinsky Reminds Erasca, Inc. Investors of Upcoming Securities Class Action Deadline - PR Newswire
ERASCA, INC. INVESTORS WITH LOSSES HAVE UNTIL AUGUST 10, - GlobeNewswire
Lead Plaintiff Deadlines in Shareholder Class Action - GlobeNewswire
Erasca (NASDAQ: ERAS) investors back board slate and KPMG auditor - Stock Titan
INVESTOR ALERT: Erasca, Inc. (ERAS) Investors with Substantial Losses Have Opportunity to Lead the Erasca Class Action Lawsuit - Finansavisen
ERAS Stock Slumps Nearly 40% After-Hours: Fine Print In 'Positive' Cancer Trial Reveals Treatment-Related Death - Stocktwits
ROSEN, A GLOBALLY RECOGNIZED FIRM, Encourages Erasca, Inc. Investors to Secure Counsel Before ... - Caledonian Record
ERAS INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Erasca, Inc. Stockholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
FinancialContentINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Erasca, Inc. of Class Action Lawsuit and Upcoming Deadlines – ERAS - FinancialContent
Erasca, Inc. (ERAS) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - GuruFocus
Form 4 Erasca Inc For: 29 June By Investing.com - Investing.com South Africa
Erasca (ERAS) director receives grant of 29,888 stock options at $16.01 - Stock Titan
[Form 4] Erasca, Inc. Insider Trading Activity - Stock Titan
Erasca (ERAS) director receives 29,888-share stock option grant at $16.01 - Stock Titan
Erasca (ERAS) director Alexander Casdin awarded 29,888 stock options at $16.01 strike - Stock Titan
Erasca (NASDAQ: ERAS) director receives stock options for 29,888 shares - Stock Titan
Erasca (NASDAQ: ERAS) director receives 29,888 stock options vesting in 2027 - Stock Titan
Erasca, Inc.(NasdaqGS: ERAS) added to Russell 2500 Growth Benchmark - marketscreener.com
Erasca, Inc. (ERAS) Faces Securities Class Action Amid Patient Death, Intellectual Property Questions, $2.8 Billion Market Cap Loss -- HBSS - Barchart.com
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of August 10, 2026 in Erasca, Inc. LawsuitERAS - GlobeNewswire
Erasca, Inc.(NasdaqGS: ERAS) dropped from Russell Microcap Value Benchmark Index - marketscreener.com
Erasca, Inc.(NasdaqGS: ERAS) dropped from Russell 2000 Value Benchmark - marketscreener.com
Erasca, Inc.(NasdaqGS: ERAS) added to Russell 2000 Growth Benchmark - marketscreener.com
Erasca, Inc.(NasdaqGS: ERAS) added to Russell 3000E Growth Benchmark - marketscreener.com
Erasca, Inc.(NasdaqGS: ERAS) dropped from Russell Microcap Index - marketscreener.com
Erasca, Inc.(NasdaqGS: ERAS) dropped from Russell Small Cap Comp Value Benchmark - marketscreener.com
Erasca, Inc.(NasdaqGS: ERAS) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com
ROSEN, A LEADING NATIONAL FIRM, Encourages Erasca, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
Kaplan Fox Alerts Erasca, Inc. (NASDAQ: ERAS) Investors to Securities Class Action LawsuitContact Before Deadline on August 7, 2026 for Leadership Role - NewMediaWire
Erasca Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against ErascaERAS - The Malaysian Reserve
ERAS Deadline Alert: The Gross Law Firm Reminds Erasca, Inc. (ERAS) Investors of Securities Class Action Deadline on August 10, 2026 - Supply Chain Digital
Finanzdaten der Erasca Inc-Aktie (ERAS)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.18%
2.70%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):